Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Human immunodeficiency virus 1 | Human immunodeficiency virus type 1 reverse transcriptase | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Trypanosoma congolense | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Plasmodium yoelii | integrase-related | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Trypanosoma brucei | RNA helicase, putative | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Schistosoma mansoni | hypothetical protein | Get druggable targets OG5_139608 | All targets in OG5_139608 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | Nitric oxide synthase, inducible | 0.0176 | 0.7743 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0198 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0198 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.01 | 0.0151 | 0.0151 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0198 | 1 | 1 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0198 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0122 | 0.2407 | 0.2407 |
Giardia lamblia | Hypothetical protein | 0.0176 | 0.7743 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0198 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0198 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0098 | 0 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0198 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.01 | 0.0158 | 0.0158 |
Trypanosoma cruzi | p450 reductase, putative | 0.0198 | 1 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0198 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0198 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0198 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0198 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0198 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0198 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0198 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0198 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0198 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0122 | 0.2407 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0198 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0198 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0198 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0198 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0198 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0098 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 102 nM | Inhibitory activity against HIV-1 reverse transcriptase | ChEMBL. | 10576692 |
IC50 (binding) | = 102 nM | Inhibitory activity against HIV-1 reverse transcriptase | ChEMBL. | 15546736 |
IC50 (binding) | = 102 nM | Inhibitory activity against HIV-1 reverse transcriptase | ChEMBL. | 10576692 |
IC50 (binding) | = 102 nM | Inhibitory activity against HIV-1 reverse transcriptase | ChEMBL. | 15546736 |
IC90 (binding) | = 6.64 nM | Inhibitory activity against HIV-1 reverse transcriptase | ChEMBL. | 10576692 |
IC90 (binding) | = 6.64 nM | Inhibitory activity against HIV-1 reverse transcriptase | ChEMBL. | 10576692 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.